Invention Grant
- Patent Title: Fused pentacyclic imidazole derivatives
-
Application No.: US15513357Application Date: 2015-10-02
-
Publication No.: US10202405B2Publication Date: 2019-02-12
- Inventor: Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
- Applicant: UCB Biopharma SPRL , Sanofi
- Applicant Address: BE Brussels
- Assignee: UCB Biopharma SPRL
- Current Assignee: UCB Biopharma SPRL
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: EP14290299 20141003; EP15162641 20150407; EP15171036 20150608
- International Application: PCT/EP2015/072868 WO 20151002
- International Announcement: WO2016/050975 WO 20160407
- Main IPC: C07D519/00
- IPC: C07D519/00 ; C07F7/18 ; C07D471/18 ; C07D487/18 ; C07D493/18 ; C07D491/08 ; A61K31/4184 ; A61K31/506 ; A61K31/55 ; C07D487/08 ; C07D491/18 ; C07D495/08 ; C07D495/18 ; C07D513/18

Abstract:
A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
Public/Granted literature
- US20170305932A1 Fused Pentacyclic Imidazole Derivatives Public/Granted day:2017-10-26
Information query